Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses

Journal of the American Academy of Dermatology

Volumn 35, Issue 6, 1996, Pages 969-979

  Tseng, Stephanie ^a   Pak, Grace ^a   Washenik, Kenneth ^a   Pomeranz, Miriam Keltz ^a   Shupack, Jerome L ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

APHTHOUS STOMATITIS; BEHCET DISEASE; CLINICAL TRIAL; DISCOID LUPUS ERYTHEMATOSUS; DROWSINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ERYTHEMA NODOSUM LEPROSUM; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PRURIGO; REVIEW; TERATOGENICITY; VERTIGO; XEROSTOMIA;

EID: 0029758257     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(96)90122-X     Document Type: Review

References (101)

1. Mellin GW, Katzenstein M. The saga of thalidomide: neuropathy to embryopathy, with case reports and congenital abnormalities. N Engl J Med 1962;23:1184-90.
2. D'Arcy PF, Griffin JP. Thalidomide revisited. Adverse Drug React Toxicol Rev 1994;13:65-76.
3. Koch HP. Thalidomide and congeners as anti-inflammatory agents. Prog Med Chem 1985;22:165-242.
4. Mellin GW, Katzenstein M. The saga of thalidomide (concluded). N Engl J Med 1962;24:1238-44.
5. Gunzler V. Thalidomide in human immunodeficiency virus (HIV) patients: a review of safety considerations. Drug Saf 1992;7:116-34.
6. Hendler S, McCarty M. Thalidomide for autoimmune disease. Med Hypotheses 1983;10:437-43.
7. Somers GF. Pharmacological properties of thalidomide (α-phthalimido glutarimide), a new sedative hypnotic drug. Br J Pharmacol 1960;15:111-6.
8. Eriksson T, Bjorkman S, Roth B, et al. Sterospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality 1995;7:44-52.
9. Chen TL, Vogelsang GB, Petty BG, et al. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab Dispos 1989;17:402-5.
10. Schumacher H, Smith RL, Williams RT. The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br J Pharmacol 1965;25:338-51.
11. Braun AG, Harding FA, Weinreb SL. Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450. Toxicol Appl Pharmacol 1986;82:175-9.
12. Hellman K, Duke DI, Tucker DF. Prolongation of skin homograft survival by thalidomide. Br Med J 1965; 2:687-9.
13. Murphy GP, Mirand EA, Groenewald JG, et al. Erythropoietin release in renal allografted baboons, with and without immunosuppression. Invest Urol 1970;7:271-82.
14. Goihman-Yahr M, Requena MA, Vallecalle-Suegart E, et al. Autoimmune diseases and thalidomide: I. adjuvant disease, experimental allergic encephalomyelitis and experimental allergic neuritis of the guinea pig. Int J Lepr 1972;40:133-41.
15. Goihman-Yahr M, Requena MA, Vallecalle-Suegart E, et al. Autoimmune diseases and thalidomide: II. adjuvant disease, experimental allergic encephalomyelitis and experimental allergic neuritis of the rat. Int J Lepr 1974; 42:266-75.
16. Faure M, Thivolet J, Gaucherand M. Inhibition of PMN leukocytes chemotaxis by thalidomide. Arch Dermatol Res 1980;269:275-80.
17. Barnhill RL, Doll NJ, Millikan LE, et al. Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes. J Am Acad Dermatol 1984;11:814-9.
18. Gad SM, Shannon EJ, Krotoski WA, et al. Thalidomide induces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males. Lepr Rev 1985; 56:35-9.
19. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes. J Exp Med 1991;173:699-703.
20. Moreira AL, Sampaio EP, Zmuidzinas A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med 1993; 177:1675-80.
21. McHugh SM, Rifkin BR, Deighton J, et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995;99:160-7.
22. Shannon EJ, Mirand RO, Morales MJ, et al. Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy. Scand J Immunol 1981;13:553-62.
23. Makonkawkeyoon S, Limson-Pobre RNR, Moreira AL, et al. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1993;90:5974-8.
24. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994;91:4082-5.
25. Schroder JM, Sellhaus B, Wohrmann T. Inhibitory effects of thalidomide on cellular proliferation, endoneurial edema and myelin phagocytosis during early Wallerian degeneration. Acta Neuropathol 1995;89:415-9.
26. Sheskin J. The treatment of lepra reaction in lepromatous leprosy: fifteen years' experience with thalidomide. Int J Dermatol 1980;19:318-22.
27. Sampaio EP, Kaplan G, Miranda A, et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993; 168:408-14.
28. Shannon EJ, Ejigu M, Haile-Mariam HS, et al. Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood. Lepr Rev 1992;63:5-11.
29. Sheskin J. Zur therapie der prurigo nodularis hyde mit thalidomid. Hautarzt 1975;26:215-7.
30. Van den Broek H. Treatment of prurigo nodularis with thalidomide. Arch Dermatol 1980;116:571-2.
31. Grosshans E, Illy G. Thalidomide therapy for inflammatory dermatoses. Int J Dermatol 1984;23:598-602.
32. Londono F. Thalidomide in the treatment of actinic prurigo. Int J Dermatol 1973;12:326-8.
33. Saul A, Flores O, Novales J. Polymorphous light eruption: treatment with thalidomide. Australas J Dermatol 1976;17:17-21.
34. Calnan CD, Meara RH. Actinic prurigo (Hutchinson's summer prurigo). Clin Exp Dermatol 1977;32:365-72.
35. Lovell CR, Hawk JLM, Calnan CD, et al. Thalidomide in actinic prurigo. Br J Dermatol 1983;108:467-71.
36. Bernal JE, Duran MM, Londono F, et al. Cellular immune effects of thalidomide in actinic prurigo [letter]. Int J Dermatol 1992;31:599-600.
37. Lo JS, Berg RE, Tomecki KJ. Treatment of discoid lupus erythematosus. Int J Dermatol 1989;28:497-507.
38. Knop J, Bonsmann G, Happle R, et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol 1983;108:461-6.
39. Atra E, Sato EI. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheum 1993;11:487-93.
40. Bessis D, Guillot B, Monpoint S. Thalidomide for systemic lupus erythematosus. Lancet 1992;339:549-50.
41. Mascaro JM, Lecha M, Torras H. Thalidomide in the treatment of recurrent, necrotic, and giant mucocutaneous aphthae and aphthosis [letter]. Arch Dermatol 1979; 115:636-7.
42. Grinspan D. Significant response of oral aphthosis to thalidomide treatment. J Am Acad Dermatol 1985;12:85-90.
43. Jenkins JS, Allen BR, Maurice PD, et al. Thalidomide in severe orogenital ulceration. Lancet 1984;2:1424-6.
44. Kurkcuoglu N, Atakan N, Eksioglu M. Thalidomide in the treatment of recurrent necrotic mucocutaneous aphthae (letter). Br J Dermatol 1985;112:632.
45. Laccourreye O, Fadlallah JP, Pages JC, et al. Sutton's disease (periadenitis mucosa necrotica recurrens). Ann Otol Rhinol Laryngol 1995;104:301-4.
46. Revuz J, Guillaume JC, Janier M, et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol 1990;126:923-7.
47. Youle M, Clarbour J, Farthing C, et al. Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. Br Med J 1989;298:432.
48. Gorin I, Vilette B, Gehanno P. Thalidomide in hyperalgic pharyngeal ulceration of AIDS [letter]. Lancet 1990;335:1343.
49. Radeff B, Kuffer R, Samson J. Recurrent aphthous ulcer in patient infected with human immunodeficiency virus: successful treatment with thalidomide. J Am Acad Dermatol 1990;23:523-5.
50. Ryan J, Colman J, Pedersen J, et al. Thalidomide to treat esophageal ulcer in AIDS [letter]. N Engl J Med 1992; 327:208-9.
51. Ghigliotti G, Repetto T, Farris A, et al. Thalidomide: treatment of choice of aphthous ulcers in patients seropositive for human immunodeficiency virus. J Am Acad Dermatol 1993;28:271-2.
52. Naum SM, Molloy PJ, Kania RJ, et al. Use of thalidomide in treatment and maintenance of idiopathic esophageal ulcers in HIV+ individuals. Dig Dis Sci 1995;40:1147-8.
53. Paterson DL, Georghiou PR, Allworth AM, et al. Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection. Clin Infect Dis 1995;20:250-4.
54. Saylan T, Saltik I. Thalidomide in the treatment of Behcet's syndrome [letter]. Arch Dermatol 1982;118:536.
55. Hamza M. Behcet's disease, palmoplantar pustulosis and HLA-B27: treatment with thalidomide [letter]. Clin Exp Rheumatol 1990;8:427.
56. Larsson H. Treatment of severe colitis in Behçet's syndrome with thalidomide (CG-217). J Int Med 1990; 228:405-7.
57. Jorizzo JL, Schmalsteig FC, Solomon AR. Thalidomide effects in Behçet' s syndrome and pustular vasculitis. Arch Intern Med 1986;146:878-81.
58. Vogelsang GB, Hess AD, Santos GW. Thalidomide for treatment of graft-versus-host disease. Bone Marrow Transplant 1988;3:393-8.
59. Lim SH, McWhannell A, Vora AJ, et al. Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation [letter]. Lancet 1988;1:117.
60. Saurat JH, Camenzind M, Helg C. Thalidomide for graft-versus-host disease after bone marrow transplantation [letter]. Lancet 1988;1:359.
61. McCarthy DM, Kanfer E, Taylor J, et al. Thalidomide for graft-versus-host disease [letter]. Lancet 1988;2:1135.
62. Heney D, Norfolk R, Wheeldon J. Thalidomide treatment for chronic graft-versus-host disease. Br J Haematol 1991;78:23-7.
63. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992;326:1055-58.
64. Wood PMD, Proctor SJ. The potential use of thalidomide in the therapy of graft-versus-host disease: a review of clinical and laboratory information. Leuk Res 1990;14: 395-9.
65. Barriere H. Sarcoides cutanees: Traitement par la thalidomide [letter]. Presse Med 1983;12:963.
66. Carlesimo M, Giustina S, Rossi A, et al. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995;32:866-9.
67. Gutierrez-Rodriguez O. Thalidomide: a promising new treatment for rheumatoid arthritis. Arthritis Rheum 1984;27:1118-21.
68. Gnassia AM, Gnassia RT, Bonvalet D, et al. Histiocytose X avec 'granulome eosinophile vulvaire': effet spectaculaire de la thalidomide. Ann Dermatol Venereol 1987; 114:1387-9.
69. Viraben R, Dupre A, Gorguet B. Pure cutaneous histiocytosis resembling sinus histiocytosis. Clin Exp Dermatol 1988;13:197-9.
70. Thomas L, Ducros B, Secchi T, et al. Successful treatment of adult's Langerhans cell histiocytosis with thalidomide. Arch Dermatol 1993;129:1261-4.
71. Misery L, Larbre B, Lyonnet S, et al. Remission of Langerhans cell histiocytosis with thalidomide treatment [letter]. Clin Exp Dermatol 1993;18:487.
72. Meunier L, Marck Y, Ribeyre C. Adult cutaneous Langerhans cell histiocytosis: remission with thalidomide treatment [letter]. Br J Dermatol 1995;132:1.
73. Venencie PY, Saurat JH. Pyoderma gangrenosum chez un enfant: traitement par la thalidomide. Ann Pediatr 1982; 29:67-9.
74. Rustin MHA, Gilkes JJH, Robinson TWE. Pyoderma gangrenosum associated with Behçet's disease: treatment with thalidomide. J Am Acad Dermatol 1990;23:941-4.
75. Munro CS, Cox NH. Pyoderma gangrenosum associated with Behçet's syndrome: response to thalidomide. Clin Exp Dermatol 1988;13:408-10.
76. Silva S, Viana PC, Lugon NV, et al. Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron 1994;67:270-3.
77. Moulin G, Bonnet F, Barrut D. Traitement de la maladie de Jessner et Kanof par la thalidomide. Ann Dermatol Venereol 1983;110:611-4.
78. Bahmer FA, Zaun H, Luszpinski P. Thalidomide treatment of recurrent erythema multiforme. Acta Derm Venereol (Stockh) 1982;62:449-50.
79. Moisson YF, Janier M, Civatte J. Thalidomide for recurrent erythema multiforme [letter]. Br J Dermatol 1992; 126:92-3.
80. Lewis HB, Albert-Recht F, Walker W. Cold haemagglutination disease treated by thalidomide. Br Soc Haematol 1968;15:322.
81. Eravelly J, Waters MF. Thalidomide in Weber-Christian disease [letter]. Lancet 1977;1:251.
82. Waters MF, Laing AB, Ambikapathy A, et al. Treatment of ulcerative colitis with thalidomide. Br Med J 1979; 1:792.
83. Barnhill RL, McDougall AC. Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. J Am Acad Dermatol 1982; 7:317-23.
84. Wallach FR, Murray HW. Thalidomide in painful AIDS-associated proctitis [letter]. J Infect Dis 1992;166:939.
85. Naafs B, Faber WR. Thalidomide therapy: an open trial. Int J Dermatol 1985;24:131-4.
86. Gunzler V. Thalidomide: A therapy for the immunological consequences of HIV infection? Med Hypotheses 1989;30:105-9.
87. Stephens TD. Proposed mechanisms of action in thalidomide embryopathy. Teratology 1988;38:229-39.
88. De Iongh RU. A quantitative ultrastractural study of motor and sensory lumbosacral nerve roots in the thalidomide-treated rabbit fetus. J Neuropathol Exp Neurol 1990; 49:564-81.
89. Fullerton PM, O'Sullivan DJ. Thalidomide neuropathy: a clinical, electrophysiological, and histological follow-up study. J Neurol Neurosurg Psychiatry 1968;31:543-51.
90. Clemmensen OJ, Olsen PZ, Andersen KE. Thalidomide neurotoxicity. Arch Dermatol 1984;120:338-41.
91. Wulff CH, Hoyer H, Asboe-Hansen G. Development of polyneuropathy during thalidomide therapy. Br J Dermatol 1985;112:475-80.
92. Ochonisky S, Verroust J, Bastuji-Garin S, et al. Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients. Arch Dermatol 1994;130:66-9.
93. Lagueny A, Rommel A, Vignolly B, et al. Thalidomide neuropathy: an electrophysiologic study. Muscle Nerve 1986;9:837-44.
94. Fuller GN, Jacobs JM, Guiloff RJ. Thalidomide, peripheral neuropathy and AIDS. Int J STD AIDS 1991;2:369-70.
95. Aronson IK, Yu R, West DP, et al. Thalidomide-induced peripheral neuropathy. Arch Dermatol 1984;120:1466-70.
96. Hess CW, Hunziker T, Kupfer A, et al. Thalidomide-induced peripheral neuropathy: a prospective clinical, neurophysiological and pharmacogenetic evaluation. J Neurol 1986;233:83-9.
97. Locker D, Superstine E, Sulman FG. The mechanism of the push and pull principle VIII: endocrine effects of thalidomide and its analogues. Arch Int Pharmacodyn Ther 1971;194:39-55.
98. Revuz J. Actualite du thalidomide. Ann Dermatol Venereol 1990;117:313-21.
99. Salafia A, Kharkar RD. Thalidomide and exfoliative dermatitis. Int J Lepr 1988;56:625.
100. Bielsa I, Teixido J, Ribera M, et al. Erythroderma due to thalidomide: report of two cases. Dermatology 1994;189: 179-81.
101. Williams I, Weller IVD, Malin A, et al. Thalidomide hypersensitivity in AIDS. Lancet 1991;337:436-7.